

Supplementary Information for:

Synthesis and Reactivity of *N,N*-1,4-diazabutadiene Derived Borocations

James R. Lawson, Lewis C. Wilkins, Manon André, Emma C. Richards, Mohammed N. Ali, James A. Platts and Rebecca L. Melen*

*School of Chemistry, Main Building, Cardiff University,
Cardiff, CF10 3AT, Cymru/Wales, U.K.*


1. Experimental

1.1 General Experimental


With the exception of the starting materials, all reactions and manipulations were carried out under an atmosphere of dry, O₂-free nitrogen using standard double-manifold techniques with a rotary oil pump. A nitrogen-filled glove box (MBraun) was used to manipulate solids including the storage of starting materials, room temperature reactions, product recovery and sample preparation for analysis. All solvents (toluene, CH₂Cl₂, hexane) were dried by a solvent purification system MB SPS-800 and stored under a nitrogen atmosphere. Deuterated solvents were distilled and/or dried over molecular sieves before use. Chemicals, namely anilines and boranes, were purchased from commercial suppliers and used as received. ¹H, ¹¹B, ¹³C, ¹⁹F, ²⁷Al and ³¹P NMR spectra were recorded on a Bruker Avance II 400 spectrometer. Chemical shifts are expressed as parts per million (ppm, δ) downfield of tetramethylsilane (TMS) and are referenced to CDCl₃ (7.26/77.16 ppm) as internal standards. NMR spectra were referenced to CFC₃ (¹⁹F), Al(NO₃)₃/D₂O (²⁷Al), BF₃·Et₂O/CDCl₃ (¹¹B) and H₃PO₄ (³¹P). The description of signals include: s = singlet, d = doublet, t = triplet, q = quartet, sep = septet, m = multiplet and br. = broad. All coupling constants are absolute values and are expressed in Hertz (Hz). ¹³C NMR was measured as ¹H decoupled. Yields are given as isolated yields. All spectra were analysed assuming a first order approximation. IR-Spectra were measured on a Shimadzu IRAffinity-1 photospectrometer. Mass spectra were measured in house on a Waters LCT Premier/XE or a Waters GCT Premier spectrometer. Elemental analyses were performed at the London Metropolitan University.

1.2 Synthesis of starting materials.


1.2.1 General synthesis 1: synthesis of 1,4-diazabutadiene precursors (1)

 In a procedure adapted from that of Yan *et al.*¹ The aniline derivative (2 equiv.) was added to a solution of 40 wt. % aqueous solution of glyoxal (1 equiv.) in ethanol (6 ml) and stirred at ambient temperature for 1 hour, unless stated otherwise. The crude product **1** precipitated as a yellow solid which was filtered off, washed with ethanol and dried thoroughly *in vacuo* to give the pure product as a yellow-brown solid.


Synthesis of (*E,E*)-*N*¹,*N*²-bis(2,6-diethylphenyl)ethane-1,2-diimine (**1a**).

 Compound **1a** was synthesised according to general synthesis 1 using 2,6-diethylaniline (1.5 ml, 9.1 mmol, 2 equiv.) and glyoxal (4.5 mmol, 1 equiv.). Analytical data agrees with the literature reported values.¹ **Yield:** 381 mg, 1.2 mmol, 26%. **¹H NMR** (400 MHz, CDCl₃, 298 K): 8.16 (s, 2H, H-C=N), 7.16 – 7.12 (m, 6H, aryl), 2.56 (q, 8H, ³J_{HH} = 7.5 Hz, CH₂), 1.21 (t, 12H, ³J_{HH} = 7.5 Hz, CH₃). **¹³C NMR** (101 MHz, CDCl₃, 298 K): 163.1 (s), 149.2 (s), 132.3 (s), 126.5 (s), 124.9 (s), 24.6 (s), 14.6 (s).


Synthesis of (*E,E*)-*N*¹,*N*²-dimesitylethane-1,2-diimine (**1b**).

 Compound **1b** was synthesised according to general synthesis 1 using 2,4,6-trimethylaniline (1.6 ml, 11 mmol, 2 equiv.) and glyoxal (5.5 mmol, 1 equiv.). Analytical data agrees with the literature reported values.¹ **Yield:** 501 mg, 1.7 mmol, 31%. **¹H NMR** (400 MHz, CDCl₃, 298 K): 8.11 (s, 2H, H-C=N), 6.92 (s, 4H, aryl), 2.31 (s, 6H, *p*-Me), 2.17 (s, 12H, *o*-Me). **¹³C NMR** (101 MHz, CDCl₃, 298 K): 163.5 (s), 147.4 (s), 134.3 (s), 129.0 (s), 126.6 (s), 20.8 (s), 18.2 (s).

Synthesis of (*E,E*)-*N*¹,*N*²-bis(4-(*tert*-butyl)phenyl)ethane-1,2-diimine (**1c**).


 Compound **1c** was synthesised according to general synthesis 1 using 4-*tert*-butylaniline (1.5 ml, 9.4 mmol, 2 equiv.) and glyoxal (4.7 mmol, 1 equiv.). Analytical data agrees with the literature reported values.¹ **Yield:** 812 mg, 2.5 mmol, 53%. **¹H NMR** (400 MHz, CDCl₃, 298 K) 8.47 (s, 2H, H-C=N), 7.49 (d, 4H, ³J_{HH} = 8.7 Hz, aryl), 7.31 (d, 4H, ³J_{HH} = 8.7 Hz, aryl), 1.38 (s, 18H, ^tBu). **¹³C NMR** (101 MHz, CDCl₃, 298 K): 159.3 (s), 151.4 (s), 147.7 (s), 126.3 (s), 121.2 (s), 34.7 (s), 31.3 (s).

Synthesis of (*E,E*)-*N*¹,*N*²-bis(2,6-diisopropylphenyl)ethane-1,2-diimine (**1d**).




Compound **1d** was synthesised according to general synthesis 1 using 2,6-diisopropylaniline (0.94 ml, 7.4 mmol, 2 equiv.) and glyoxal (3.7 mmol, 1 equiv.). Analytical data agrees with the literature reported values.¹ **Yield:** 679 mg, 1.8 mmol, 49%. **¹H NMR** (400 MHz, CDCl₃, 298 K): 8.10 (s, 2H, H-C=N), 7.16-7.04 (m, 6H, aryl), 2.87 (sep, 4H, ³J_{HH} = 6.8 Hz, ⁱPr H), 1.14 (d, 24H, ³J_{HH} = 6.8 Hz, ⁱPr Me). **¹³C NMR** (101 MHz, CDCl₃, 298 K): 163.1 (s), 148.0 (s), 136.7 (s), 125.1 (s), 123.2 (s), 28.0 (s), 23.4 (s).

Synthesis of (*E,E*)-*N*¹,*N*²-bis(4-bromo-2,6-diethylphenyl)ethane-1,2-diimine (**1e**).




Compound **1e** was synthesised according to general synthesis 1 using 2,6-diethyl-4-bromoaniline (1.18 ml, 7.4 mmol, 2 equiv.) and glyoxal (3.7 mmol, 1 equiv.). **Yield:** 754 mg, 1.6 mmol, 43%. **¹H NMR** (400 MHz, CDCl₃, 298 K): 8.00 (s, 2H, H-C=N), 7.16 (s, 4H, aryl), 2.40 (q, 8H, ³J_{HH} = 7.6 Hz, CH₂), 1.08 (t, 12H, ³J_{HH} = 7.5 Hz, CH₃). **¹³C NMR** (101 MHz, CDCl₃, 298 K): 163.1 (s), 148.0 (s), 136.7 (s), 125.1 (s), 123.2 (s), 28.0 (s), 23.4 (s). **MP:** 104-106 °C. **IR** ν_{\max} (cm⁻¹): 2963, 2936, 2876, 1618, 1609, 1572, 1454, 1441, 1408, 1371, 1327, 1304, 1271, 1233, 1173, 1022, 964, 872, 860, 841, 800, 779, 756, 702, 615, 586, 552. **HRMS (ES⁺)** [M+H]⁺ [C₂₂H₂₇N₂Br₂]⁺: calculated: 477.0541 found: 477.0527. **EA (%)** for C₂₂H₂₆N₂Br₂: Calculated C 55.25, H 5.48, N 5.86, Found C 55.14, H 5.36, N 5.95.

Synthesis of (*E,E*)-*N*¹,*N*²-bis(2,4,6-tri-*tert*-butylphenyl)ethane-1,2-diimine (**1f**).



Compound **1f** was synthesised according to general synthesis 1, but was heated to reflux for 72 hours using 2,4,6-tri-*tert*-butylaniline (0.48 mg, 1.85 mmol, 2 equiv.) and glyoxal (0.92 mmol, 1 equiv.). Analytical data agrees with the literature reported values.¹ **Yield:** 117 mg, 0.2 mmol, 23%. **¹H NMR** (400 MHz, CDCl₃, 298 K): 8.16 (s, 2H, H-C=N), 7.38 (s, 4H, aryl), 1.36 (s, 36H, *o*^tBu), 1.35 (s, 18H, *p*^tBu). **¹³C NMR** (101 MHz, CDCl₃, 298 K): 163.4 (s), 149.3 (s), 145.0 (s), 137.4 (s), 121.9 (s), 36.0 (s), 34.8 (s), 31.5 (s).


Synthesis of (*E,E*)-*N*¹,*N*²-bis(4-methoxyphenyl)ethane-1,2-diimine (**1g**).



Compound **1c** was synthesised according to general synthesis 1 using 4-methoxyaniline (1.5 g, 12 mmol, 2 equiv.) and glyoxal (6 mmol, 1 equiv.). Analytical data agrees with the literature reported values.¹ **Yield:** 1.25 g, 4.7 mmol, 76%. **¹H NMR** (400 MHz, CDCl₃, 298 K): 8.43 (s, 2H, H-C=N), 7.35 (d, ³J_{HH} = 8.5 Hz, 4H, aryl), 6.97 (d, ³J_{HH} = 8.5 Hz, 4H, aryl), 3.86 (s, 6H, OMe). **¹³C NMR** (101 MHz, CDCl₃, 298 K): 159.8 (s), 157.6 (s), 142.9 (s), 123.1 (s), 114.6 (s), 55.6 (s).

1.3 Synthesis of products


1.3.1 General synthesis 2: synthesis of borenium cations (3)



Diazabutadiene **1** (0.1 mmol, 1 equiv.) was dissolved in CDCl_3 (ca. 0.6 ml), to which PhBCl_2 (16 mg, 0.1 mmol, 1 equiv.) was added. Formation of the intermediate **2** was complete within 10 minutes, as monitored by *in situ* multinuclear NMR spectroscopy.

Upon completion, AlCl_3 (13 mg, 0.1 mmol, 1 equiv.) was added to give a dark red/brown coloured solution. The solvent was reduced and layered with hexane and stored at -40°C to yield either a solid precipitate or a crop of red/brown coloured crystals suitable for X-ray diffraction. The solvent was then removed and the crystals were subsequently washed with cold hexane (3×2 ml) then dried *in vacuo* to give the pure product **3**.


1.3.2 General synthesis 3: synthesis of boronium cations (4)



Diazabutadiene **1** (0.1 mmol, 1 equiv.) was dissolved in CDCl_3 (ca. 0.6 ml), to which BCl_3 (0.2 ml, 1M in DCM, 0.2 mmol, 2 equiv.) was added, instantly forming a dark red solution. Monitoring by *in situ* multinuclear NMR spectroscopy showed that the reaction was complete within 10 minutes. Upon completion, AlCl_3 (13 mg, 0.1 mmol,


1 equiv.) was added to give a deep red coloured solution. The solvent was reduced and layered with hexane and stored at -40°C to yield a crop of red coloured crystals suitable for X-ray diffraction. The remaining solvent was removed and the crystals were subsequently washed with cold hexane (3×2 ml) then dried *in vacuo* to give the pure product.

Synthesis of 4-chloro-1,3-bis(2,6-diethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3a).




Compound **3a** was synthesised using general synthesis 2 using diazabutadiene **1a** (32 mg, 0.1 mmol). Yield: 56 mg, 0.09 mmol, 91%. After multiple EA attempts satisfactory results could not be obtained. $^1\text{H NMR}$ (400 MHz, CDCl_3 , 298 K): 7.67 (t, $^3J_{\text{HH}} = 7.7$ Hz, 1H, *p*-aryl), 7.45 (d, $^3J_{\text{HH}} = 7.6$ Hz, 2H), 7.40 (t, $^3J_{\text{HH}} = 7.5$ Hz, 2H), 7.32 (d, $^3J_{\text{HH}} = 7.7$ Hz, 2H), 7.10 (t, $^3J_{\text{HH}} = 7.9$ Hz, 2H), 6.83 (d, $^3J_{\text{HH}} = 7.2$ Hz, 2H), 5.60 (s, 2H, N- CH_2), 2.74-2.36 (m, 8H, CH_2), 1.23-1.17 (m, 12H, CH_3). $^{11}\text{B NMR}$ (128 MHz, CDCl_3 , 298 K): 34.4 (s). $^{13}\text{C NMR}$ (101 MHz, CDCl_3 , 298 K): 140.1 (s), 137.2 (s), 134.4 (s), 133.7 (s), 133.6 (s), 133.2 (s), 132.2 (s), 129.9 (s), 128.8 (s), 128.1 (s), 127.5 (s), 65.8 (s), 24.6 (s), 24.2 (s), 14.3 (s), 13.7 (s). $^{27}\text{Al NMR}$ (104 MHz, CDCl_3 , 298 K): 103.92 (s).

Synthesis of 4-chloro-1,3-bis(2,4,6-trimethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3b**).




Compound **3b** was synthesised using general synthesis 2 using diazabutadiene **1b** (30 mg, 0.1 mmol). Yield: 55 mg, 0.1 mmol, 95%. ¹H NMR (400 MHz, CDCl₃, 298 K): 7.44 (t, ³J_{HH} = 7.5 Hz, 1H, *p*-aryl), 7.18-7.15 (m, 6H), 6.91 (d, ³J_{HH} = 7.1 Hz, 2H, *o*-aryl), 5.54 (s, 2H, N-CH₂), 2.46 (s, 3H, *p*-Me), 2.36 (s, 3H, *p*-Me), 2.25 (s, 6H, *o*-Me), 2.20 (s, 6H, *o*-Me). ¹¹B NMR (128 MHz, CDCl₃, 298 K): 33.9 (br s). ¹³C NMR (101 MHz, CDCl₃, 298 K): 191.0 (s), 142.3 (s), 139.3 (s), 134.1 (s), 133.5 (s), 133.1 (s), 132.8 (s), 131.6 (s), 131.4 (s), 130.9 (s), 130.5 (s), 128.9 (s), 64.8 (s), 21.3 (s), 21.1 (s), 18.2 (s), 18.0 (s). ²⁷Al NMR (104 MHz, CDCl₃, 298 K): 103.96 (s).

Synthesis of 4-chloro-1,3-bis(2,6-diisopropylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3d**).



Compound **3d** was synthesised using general synthesis 2 using diazabutadiene **1d** (33 mg, 0.1 mmol). Yield: 62 mg, 0.09 mmol, 92%. ¹H NMR (400 MHz, CDCl₃, 298 K): 7.73 (t, ³J_{HH} = 7.9 Hz, 1H, *p*-aryl), 7.53-7.48 (m, 3H), 7.38 (t, ³J_{HH} = 7.6 Hz, 1H, *p*-aryl), 7.33 (d, ³J_{HH} = 7.8 Hz, 2H, aryl), 7.08 (t, ³J_{HH} = 7.8 Hz, 2H, *m*-aryl), 6.78 (d, ³J_{HH} = 7.3 Hz, 2H, *o*-aryl), 5.64 (s, 2H, N-CH₂), 2.94 (sep, ³J_{HH} = 6.7 Hz, 2H, ⁱPr H), 2.61 (sep, ³J_{HH} = 6.7 Hz, 2H, ⁱPr H), 1.36 (2d (overlapped), ³J_{HH} = 6.5 Hz, 12H, ⁱPr Me), 0.98 (d, ³J_{HH} = 6.7 Hz, 12H, ⁱPr Me). ¹¹B NMR (128 MHz, CDCl₃, 298 K): 31.8 (s). ¹³C NMR (101 MHz, CDCl₃, 298 K): 190.7 (s), 145.2 (s), 142.3 (s), 134.6 (s), 133.7 (s), 132.7 (s), 131.4 (s), 130.3 (s), 128.5 (s), 126.1 (s), 125.4 (s), 66.9 (s), 30.1 (s), 29.0 (s), 25.2 (s), 24.3 (s), 23.9 (s), 23.3 (s). ²⁷Al NMR (104 MHz, CDCl₃, 298 K): 103.97 (s). EA (%) for C₃₂H₄₁N₂AlBCl₅: Calculated C 57.47, H 6.18, N 4.19, Found C 57.63, H 6.33, 4.27.


Synthesis of 4-chloro-1,3-bis(2,6-diethyl-4-bromophenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3e**).



Compound **3e** was synthesised using general synthesis 2 using diazabutadiene **1e** (48 mg, 0.1 mmol). Yield: 64 mg, 0.08 mmol, 83%. ¹H NMR (400 MHz, CDCl₃, 298 K): 7.61 (s, 2H, *m*-aryl), 7.48 (t, 1H, *p*-aryl), 7.45 (s, 2H, *m*-aryl), 7.20 (t, 2H, *m*-aryl), 6.86 (d, 2H, *o*-aryl), 5.52 (s, 2H, N-CH₂), 2.68-2.32 (m, 8H, CH₂), 1.22-1.17 (m, 12H, CH₃). ¹¹B NMR (128 MHz, CDCl₃, 298 K): 33.4 (s). ¹³C NMR (101 MHz, CDCl₃, 298 K): 191.6 (s), 142.1 (s), 139.2 (s), 133.5 (s), 131.4 (s), 130.7 (s), 129.2 (s), 126.9 (s), 124.3 (s), 65.6 (s), 24.5 (s), 24.1 (s), 14.0 (s), 13.4 (s). ²⁷Al NMR (104 MHz, CDCl₃, 298 K): 103.82


(s). **EA** (%) for $C_{28}H_{31}N_2AlBCl_5Br_2$: Calculated C 43.65, H 4.06, N 3.64, Found C 43.57, H 4.14, N 3.72.

Synthesis of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3l4,2l4-diazaborol-1-ium (4a).




Compound **4a** was synthesised using general synthesis 3 using diazabutadiene **1a** (32 mg, 0.1 mmol). Yield: 56 mg, 0.1 mmol, 98%. $^1\text{H NMR}$ (400 MHz, CDCl_3 , 298 K): 9.53 (s, 2H, N=C-H), 7.52 (t, 2H, $^3J_{\text{HH}} = 7.7$ Hz, *p*-aryl), 7.38 (d, 4H, $^3J_{\text{HH}} = 7.7$ Hz, *m*-aryl), 2.79-2.62 (m, 8H, CH_2), 1.31 (t, 12H, $^3J_{\text{HH}} = 7.6$ Hz, CH_3). $^{11}\text{B NMR}$ (128 MHz, CDCl_3 , 298 K): 10.6 (s). $^{13}\text{C NMR}$ (101 MHz, CDCl_3 , 298 K): 165.0 (s), 138.2 (s), 133.7 (s), 131.2 (s), 127.4 (s), 24.9 (s), 15.2 (s). $^{27}\text{Al NMR}$ (104 MHz, CDCl_3 , 298 K): 103.98 (s).

Synthesis of 2,2-dichloro-1,3-dimesityl-2H-1,3l4,2l4-diazaborol-1-ium (4b).



Compound **4b** was synthesised using General synthesis 3 using diazabutadiene **1b** (30 mg, 0.1 mmol). Yield: 53 mg, 0.1 mmol, 98%. $^1\text{H NMR}$ (400 MHz, CDCl_3 , 298 K): 9.48 (s, 2H, N=C-H), 7.08 (s, 4H, Ar-H), 2.41 (s, 12H, *o*-Me), 2.37 (s, 6H, *p*-Me). $^{11}\text{B NMR}$ (128 MHz, CDCl_3 , 298 K): 10.6 (br. s). $^{13}\text{C NMR}$ (101 MHz, CDCl_3 , 298 K): 165.2 (s), 141.2 (s), 133.2 (s), 132.2 (s), 130.9 (s), 20.8 (s), 19.4 (s). $^{27}\text{Al NMR}$ (104 MHz, CDCl_3 , 298 K): 103.81 (s).

Synthesis of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3l4,2l4-diazaborol-1-ium (4e).




Compound **4d** was synthesised using general synthesis 3 using diazabutadiene **1e** (48 mg, 0.1 mmol). Yield: 46 mg, 0.06 mmol, 63%. $^1\text{H NMR}$ (400 MHz, CDCl_3 , 298 K): 9.43 (s, 2H), 7.51 (s, 4H), 2.75-2.55 (m, 8H, CH_2), 1.31 (t, 12H, $^3J_{\text{HH}} = 7.4$ Hz, CH_3). $^{11}\text{B NMR}$ (128 MHz, CDCl_3 , 298 K): 10.5. $^{13}\text{C NMR}$ (101 MHz, CDCl_3 , 298 K): 165.0 (s), 140.6 (s), 132.4 (s), 130.8 (s), 126.2 (s), 25.1 (s), 15.4 (s). $^{27}\text{Al NMR}$ (104 MHz, CDCl_3 , 298 K): 103.81 (s).


2. Experimental: NMR spectra

2.1 NMR spectra of starting materials.


S1 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(2,6-diethylphenyl)ethane-1,2-diimine (**1a**).




S2 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)-*N*¹,*N*²-bis(2,6-diethylphenyl)ethane-1,2-diimine (**1a**).




S3 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -dimesitylethane-1,2-diimine (**1b**).




S4 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum (*E,E*)- N^1,N^2 -dimesitylethane-1,2-diimine (**1b**).




S5 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(4-(*tert*-butyl)phenyl)ethane-1,2-diimine (**1c**).




S6 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum (*E,E*)- N^1,N^2 -bis(4-(*tert*-butyl)phenyl)ethane-1,2-diimine (**1c**).




S7 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(2,6-diisopropylphenyl)ethane-1,2-diimine (**1d**).




S8 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(2,6-diisopropylphenyl)ethane-1,2-diimine (**1d**).




S9 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(4-bromo-2,6-diethylphenyl)ethane-1,2-diimine (**1e**).




S10 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(4-bromo-2,6-diethylphenyl)ethane-1,2-diimine (**1e**).




S11 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(2,4,6-tri-*tert*-butylphenyl)ethane-1,2-diimine (**1f**).




S12 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of *(E,E)*- N^1,N^2 -bis(2,4,6-tri-*tert*-butylphenyl)ethane-1,2-diimine (**1f**).



S13 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(4-methoxyphenyl)ethane-1,2-diimine (**1g**).




S14 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of (*E,E*)- N^1,N^2 -bis(4-methoxyphenyl)ethane-1,2-diimine (**1g**).




2.2 NMR spectra of products.


S15 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diethylphenyl)-2-phenyl-2,3-dihydro-1H-1,3,2-diazaborole (**2a**).




S16 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,6-diethylphenyl)-2-phenyl-2,3-dihydro-1H-1,3,2-diazaborole (2a)*.




S17 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diethylphenyl)-2-phenyl-2,3-dihydro-1H-1,3,2-diazaborole (**2a**).




S18 ¹H NMR (400 MHz, CDCl₃, 298 K) spectrum of 4-chloro-1,3-bis(2,4,6-trimethylphenyl)-2-phenyl-2,3-dihydro-1H-1,3,2-diazaborole (**2b**).




S19 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,4,6-trimethylphenyl)-2-phenyl-2,3-dihydro-1H-1,3,2-diazaborole (2b)*.




S20 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,4,6-trimethylphenyl)-2-phenyl-2,3-dihydro-1H-1,3,2-diazaborole (**2b**).




S21 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3a**).




S22 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,6-diethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3a)*.




S23 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3a**).




S24 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,6-diethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3a)*.




S25 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,4,6-trimethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3b**).




S26 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,4,6-trimethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3b)*.




S27 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,4,6-trimethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3b**).




S28 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,4,6-trimethylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3b)*.




S29 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diisopropylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3d**).




S30 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diisopropylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3d**).




S31 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diisopropylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3d**).




S32 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,6-diisopropylphenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3d)*.




S33 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diethyl-4-bromophenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (**3e**).




S34 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,6-diethyl-4-bromophenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3e)*.




S35 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of 4-chloro-1,3-bis(2,6-diethyl-4-bromophenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3e).




S36 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of *4-chloro-1,3-bis(2,6-diethyl-4-bromophenyl)-2-phenyl-2,5-dihydro-1H-1,3,2-diazaborol-3-ium tetrachloroaluminate (3e)*.




S37 *in situ* ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3l4,2l4-diazaborol-1-ium (**4a**).




S38 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3/4,2/4-diazaborol-1-ium (**4a**).




S39 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3,4,2,14-diazaborol-1-ium (**4a**).




S40 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3l4,2l4-diazaborol-1-ium (**4a**).




S41 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-dimesityl-2H-1,3l4,2l4-diazaborol-1-ium (**4b**).




S42 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-dimesityl-2H-1,3l4,2l4-diazaborol-1-ium (**4b**).




S43 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-dimesityl-2H-1,3l4,2l4-diazaborol-1-ium (**4b**).




S44 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-dimesityl-2H-1,3l4,2l4-diazaborol-1-ium (**4b**).




S45 ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3,4,2,14-diazaborol-1-ium (**4e**).




S46 ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3/4,2/4-diazaborol-1-ium (**4e**).




S47 ^{13}C NMR (101 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3,14,21,4-diazaborol-1-ium (**4e**).




S48 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of 2,2-dichloro-1,3-bis(2,6-diethylphenyl)-2H-1,3,4,2H-diazaborol-1-ium (**4e**).




S49 *in situ* ^1H NMR (400 MHz, CDCl_3 , 298 K) spectrum of the reaction of **3a** with tri(*o*-tolyl)phosphine.




S50 *in situ* ^{11}B NMR (400 MHz, CDCl_3 , 298 K) spectrum of the reaction of **3a** with tri(*o*-tolyl)phosphine.




S51 *in situ* ^{31}P NMR (162 MHz, CDCl_3 , 298 K) spectrum of the reaction of **3a** with tri(*o*-tolyl)phosphine.




S52 *in situ* $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3 , 298 K) spectrum of the reaction of **3a** with tri(*o*-tolyl)phosphine.




S53 *in situ* ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of the reaction of **3a** with tri(*o*-tolyl)phosphine.




S54 *in situ* overlay ^{11}B NMR (128 MHz, CDCl_3 , 298 K) spectrum of the reaction of **1b** with 1 equiv. BCl_3 (red) and 2 equiv. BCl_3 (blue).




S55 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of **3a** + Ph_3PO




S56 ^{31}P NMR (162 MHz, CDCl_3 , 298 K) spectrum of **3a** + Ph_3PO




S57 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of **3b** + Ph_3PO




S58 ^{31}P NMR (162 MHz, CDCl_3 , 298 K) spectrum of **3b** + Ph_3PO




S59 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of **3d** + Ph_3PO




S60 ^{31}P NMR (162 MHz, CDCl_3 , 298 K) spectrum of **3d** + Ph_3PO




S61 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of **3e** + Ph_3PO



S62 ^{31}P NMR (162 MHz, CDCl_3 , 298 K) spectrum of **3e** + Ph_3PO




S63 ^{27}Al NMR (104 MHz, CDCl_3 , 298 K) spectrum of $\text{AlCl}_3 + \text{Ph}_3\text{PO}$



S64 ^{31}P NMR (162 MHz, CDCl_3 , 298 K) spectrum of $\text{AlCl}_3 + \text{Ph}_3\text{PO}$


~46.31
~42.09




3. Crystallographic studies.

3.1 Thermal ellipsoid plots


S65 Thermal ellipsoid of 3a (ellipsoid probability 50 %). C: black, N: blue, B: yellow-green, H: white, Al: grey, Cl: aquamarine.



S66 Thermal ellipsoid of **3d** (ellipsoid probability 50 %). C: black, N: blue, B: yellow-green, H: white, Al: grey, Cl: aquamarine.



S67 Thermal ellipsoid of **4a** (ellipsoid probability 50 %). C: black, N: blue, B: yellow-green, H: white, Al: grey, Cl: aquamarine.



3.2 Refinement data

Single crystals of **3a** and **3d** were grown under an inert atmosphere. Crystallographic studies were undertaken of a single crystal mounted in paratone and studied on an Agilent SuperNova Dual Atlas three-circle diffractometer using Cu-K α or Mo-K α radiation and a CCD detector. Measurements were carried out at 150(2) K or 100(2) K (**3d**) with temperatures maintained using an Oxford cryostream unless otherwise stated. Data were collected and integrated and data corrected for absorption using a numerical absorption correction based on gaussian integration over a multifaceted crystal model within CrysAlisPro.² The structures were solved by direct methods and refined against F^2 within SHELXL-2013.³ A summary of crystallographic data are available as ESI and the structures deposited with the Cambridge Structural Database (CCDC deposition numbers 1499077 (**3a**), 1499078 (**3d**), 1499079 (**4a**)). These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif

Table S1. Crystallographic data for **3a** and **3d**.

Compound	3a	3d
Empirical Formula	C ₂₈ H ₃₃ AlBCl ₅ N ₂	C ₃₂ H ₄₁ AlBCl ₅ N ₂
Crystal System	Triclinic	Orthorhombic
Space Group	<i>P</i> -1	<i>P</i> 2 ₁ 2 ₁ 2
<i>a</i> /Å	9.7882(4)	18.9942(4)
<i>b</i> /Å	11.2460(5)	18.2174(4)
<i>c</i> /Å	14.7984(6)	10.5733(2)
α /°	88.786(4)	90
β /°	79.559(4)	90
γ /°	74.904(4)	90
<i>V</i> /Å ³	1546.35(12)	3658.63(15)
<i>Z</i>	2	4
<i>T</i> /K	150(2)	100(2)
<i>D_c</i> /g.cm ⁻³	1.316	1.214
Crystal size/mm	0.354 x 0.252 x 0.236	0.070 x 0.050 x 0.040
Total data	12778	41108
Unique data	7336	6461
<i>R</i> _{int}	0.0373	0.0573
<i>R</i> ₁ [<i>F</i> ² >2 σ (<i>F</i> ²)]	0.0451	0.0350
w <i>R</i> ₂ (all data)	0.1168	0.0843
GoF	1.006	1.023
ρ _{min} / ρ _{max} /eÅ ⁻³	-0.631/0.656	-0300/0.333
CCDC code	1499077	1499078

4. Computational studies.

All geometry optimisations were undertaken using the B3LYP functional⁴ and 6-31G* basis set⁵ within Gaussian 09.⁶ Subsequent single point calculations were undertaken using the B3LYP functional and larger 6-311G* basis set. In addition, partial charges were determined using an NBO analysis.⁷

Figure S68. Overlay of geometry optimised structure and experimental solid-state crystal structure of **3a** (left) and **4a** (right).





Figure S69. Key NBO charge distributions for **3a** (left) and **4a** (right)



References

1. K. Yan, C. N. Lok, K. Bierla and C. M. Che, *Chem. Commun.*, 2010, **46**, 7691.
2. CrysAlisPro, Agilent Technologies, Version 1.171.37.33 (release 27-03-2014 CrysAlis171.NET).
3. SHELXL-2013, G. M. Sheldrick, University of Göttingen, Germany (2013).
4. A. D. Becke, *Phys. Rev. A*, 1988, **38**, 3098; C. Lee, W. Yang, R. G. Parr. *Phys. Rev. B*, 1988, **37**, 785.
5. R. Ditchfield, W. J. Hehre, J. A. Pople, *J. Chem. Phys.* 1971, **54**, 724
6. Gaussian 09, Revision C.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B.

Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2009.

7. NBO 6.0. J. K. Glendening, A. E. Reed, J. E. Carpenter, J. A. Bohmann, C. M. Morales, C. R. Landis, F. Weinhold. (Theoretical Chemistry Institute, University of Wisconsin, Madison, WI, 2013); <http://Nbo6.Chem.Wisc.Edu/>.